Fosamax Osteonecrosis of the Jaw Causation: How Fosamax Triggers Osteonecrosis of the Jaw Pathophysiology

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specialized Risk Assessment

The legacy context of general health and science information has long emphasized the importance of understanding how medications interact with biological systems to maintain wellness. Within this framework, the focus has traditionally been on therapeutic benefits and broad safety profiles, with less attention to specific, rare adverse events that may emerge in particular patient populations. As scientific inquiry deepens, the transition from general health awareness to more specialized risk assessment becomes necessary, especially when considering long-term medication use and its potential consequences. This shift naturally leads to an occupational exposure concern, where the focus moves from population-level health guidance to the specific circumstances of individuals who may face heightened vulnerability due to their work environment. In settings where handling or administering pharmaceuticals is routine, the potential for unintended exposure or cumulative effects requires careful evaluation. The concern here is not about disease mechanisms, but about the practical implications of sustained contact with substances that, under certain conditions, may pose risks to oral health. This transition underscores the need for vigilance in occupational health protocols, ensuring that workers are informed and protected as the understanding of medication-related risks evolves beyond general health contexts.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the need for specialized risk assessment, this article examines the specific case of Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology linking Fosamax to ONJ involves complex mechanisms at the cellular and tissue levels, particularly in the jawbone.

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The jawbone exhibits unique structural and metabolic properties that may predispose it to bisphosphonate-related complications. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies using animal models have examined the effects of bisphosphonate (alendronate) on the jawbone, including assessments of static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These investigations suggest that bisphosphonate treatment alters the mechanical and material properties of the jawbone, potentially contributing to the development of ONJ. The clinical presentation of ONJ in patients taking Fosamax typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Evidence

Regarding causation considerations for affected patients, the evidence indicates that Fosamax can trigger ONJ through its effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, which reduces bone turnover. In the jawbone, this suppression of remodeling may impair the ability to repair microdamage and respond to local infections or trauma, leading to necrosis. The multiscale characterization of jawbone treated with osteoporosis therapeutic agents highlights that bisphosphonate treatment alters tissue mineral density distribution and mechanical properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes may compromise the structural integrity of the jawbone and its ability to heal after dental procedures. The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also identifies known risk factors and notes that the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label recommends discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to potentially reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm from ONJ is variable. Symptoms can appear as early as one day after starting the drug or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition is often triggered by dental procedures, and the risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, the condition can be challenging to manage and may require discontinuation of the bisphosphonate and specialized dental care.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast activity, reducing bone turnover. In the jawbone, this suppression of remodeling impairs the ability to repair microdamage and respond to local infections or trauma, leading to necrosis. Studies show that bisphosphonate treatment alters tissue mineral density distribution and mechanical properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How soon after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset of symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition is often triggered by dental procedures, and the risk increases with longer duration of use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.